News & Media

Take a closer look at what we’re doing across Teva in Canada and worldwide

Teva Canada Limited, headquartered in Toronto, and Teva Canada Innovation, headquartered in Montréal, are part of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug maker. We’re proud to have been part of Canadian healthcare for more than 50 years, to market more than 400 medications across the country and to employ more than 1,000 Canadians.

If you’re looking for information about our company, please contact Public Affairs at Teva Canada Limited at Public.Affairs@tevacanada.com.

Latest news

Read the latest Teva news

Important Information: ratio-Ectosone (Teva-Ectosone) Type I Recall to Consumer Level

Important Information: ratio-Ectosone (Teva-Ectosone) Type I Recall to Consumer Level

Teva Canada welcomes Fabien Paquette as new General Manager

Teva Canada welcomes Fabien Paquette as new General Manager

Important Information - Voluntary Nationwide Recall ratio-Ectosone (TEVA-ECTOSONE) 0.05% Mild lotion...

Important Information - Voluntary Nationwide Recall ratio-Ectosone (TEVA-ECTOSONE) 0.05% Mild lotion 60mL (DIN 00653209)

Important Information on Nicotine Patches

Important Information on Nicotine Patches

Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry

Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry

Government Tour of Teva Canada’s Stouffville Manufacturing Facility Showcases Pharmaceutical Capabil...

Government Tour of Teva Canada’s Stouffville Manufacturing Facility Showcases Pharmaceutical Capabilities and Underscores Economic Value to Canada

Important Safety Information on Codeine Antitussive Products

Important Safety Information on Codeine Antitussive Products

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of prov...

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the preventive treatment of migraine in adults

New public drug plan reimbursement for AJOVY®

New public drug plan reimbursement for AJOVY®

Important Information – Voluntary Nationwide Recall - Novo-Gesic Forte® 500 mg (Acetaminophen) Table...

Important Information – Voluntary Nationwide Recall - Novo-Gesic Forte® 500 mg (Acetaminophen) Tablets
View all news articles
Previous
Next

Featured stories

Teva’s 2023 Healthy Future Report

Teva’s 2023 Healthy Future Report

Meet the Expert: Alpa Jani, Director of Regulatory Affairs, Teva Canada

Meet the Expert: Alpa Jani, Director of Regulatory Affairs, Teva Canada

Meet the Expert: Stuart Lourie, Senior Director of Marketing, Teva Canada Innovation

Meet the Expert: Stuart Lourie, Senior Director of Marketing, Teva Canada Innovation

Meet Corrine Dias, Teva Canada employee for 12 years

Meet Corrine Dias, Teva Canada employee for 12 years

Meet Erin Rose, Teva Canada employee for 13 years

Meet Erin Rose, Teva Canada employee for 13 years

Meet Gina Cameron, Teva Canada Employee for 10 years!

Meet Gina Cameron, Teva Canada Employee for 10 years!

Meet Sandy Lee, Teva Canada Employee for 34 years

Meet Sandy Lee, Teva Canada Employee for 34 years
View all featured stories